Elisa Agostinetto: Datopotamab-Deruxtecan in HR+/HER2-low or negative metastatic breast cancer

Elisa Agostinetto shared a post on X:

”A press release from industry announces that TROPION-Breast01 testing Datopotamab-Deruxtecan versus chemotherapy in hormone receptor-positive/human epidermal growth factor receptor 2 (HR+/HER2)-low or negative metastatic breast cancer did not achieve statistical significance in overall survival.

The trial had met the primary endpoint of progression-free survival (presented at the European Society for Medical Oncology 2023 Congress).”

Source: Elisa Agostinetto/X

Elisa Agostinetto, is a medical oncologist, specializing in breast cancer research. Elisa Agostinetto is a Medical Research Fellow at the University Hospital of Brussels since November 2021. Additionally, she has serves as a Clinical Research Fellow at Jules Bordet Institute. Her work focuses on clinical research in oncology, likely involving various aspects of cancer treatment and patient care. Actively engaged in professional societies like ESMO, ASCO, and BSMO, she also contributes as a young investigator in the EORTC Breast Cancer Working Group and as a Committee member of the Young Cancer Professionals within the European Cancer Organization.